ClinicalTrials.gg
WithdrawnNCT07524257Updated Jun 22, 2026

Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

A Phase 3 interventional study of Drug: Nogapendekin alfa inbakicept (NAI) and Pembrolizumab in NSCLC (Advanced Non-small Cell Lung Cancer) and Metastatic NSCLC, sponsored by ImmunityBio, Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by ImmunityBio, Inc. · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, open-label, phase 3 study evaluating nogapendekin alfa inbakicept (NAI) plus chemoimmunotherapy containing pembrolizumab and platinum-based chemotherapy versus chemoimmunotherapy alone as first-line treatment in patients with stage IV squamous or nonsquamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Primary endpoint is progression-free survival by RECIST v1.1 based on blinded independent central review.

Read the detailed description

This is a phase 3, randomized, open-label, parallel-group clinical trial evaluating nogapendekin alfa inbakicept (NAI; an IL-15 receptor agonist) in combination with standard first-line chemoimmunotherapy versus standard chemoimmunotherapy alone in participants with stage IV squamous or nonsquamous non-small cell lung cancer (NSCLC) without actionable genomic alterations that have approved targeted therapies. Approximately 494 participants will be randomized 1:1 to receive either NAI plus pembrolizumab and platinum-based chemotherapy (experimental arm) or pembrolizumab and platinum-based chemotherapy alone (control arm), with the possibility of increasing the sample size up to 960 participants based on an interim progression-free survival (PFS) analysis.

In the experimental arm, participants receive induction therapy for up to 4 cycles (21-day cycles) with pembrolizumab 200 mg IV plus cisplatin 75 mg/m² IV or carboplatin AUC 5-6 IV, and a histology-specific third agent (nab-paclitaxel 100 mg/m² IV on Days 1, 8, and 15 for squamous NSCLC, or pemetrexed 500 mg/m² IV on Day 1 for nonsquamous NSCLC), in combination with NAI 1.2 mg subcutaneously (SC) on Day 1 of each cycle (participants ≥100 kg receive NAI 15 μg/kg SC). In the maintenance phase (cycles ≥5), participants in the experimental arm continue pembrolizumab 200 mg IV every 3 weeks with NAI 1.2 mg SC every 3 weeks, with pemetrexed 500 mg/m² IV continued in nonsquamous NSCLC. In the control arm, participants receive the same pembrolizumab plus platinum backbone, with squamous participants receiving either nab-paclitaxel, paclitaxel, or docetaxel per regional product labeling, and nonsquamous participants receiving pemetrexed, followed by maintenance pembrolizumab with or without pemetrexed according to histology. All study treatment is administered for up to 35 cycles (approximately 2 years), or until disease progression, unacceptable toxicity, withdrawal of consent, or investigator decision.

Tumor assessments (CT or MRI) are performed at screening, at week 6 and week 12 following Cycle 1 Day 1, and every 9 weeks (±7 days) thereafter, and tumor response is evaluated per RECIST v1.1 and immune RECIST (iRECIST). The primary endpoint is PFS per RECIST v1.1 as assessed by blinded independent central review (BICR). Key secondary endpoints include overall survival (OS) and objective response rate (ORR) per RECIST v1.1 by BICR. Other secondary endpoints include PFS, ORR, duration of response (DOR), and disease control rate (DCR) by iRECIST (BICR) and by Investigator assessment, change in absolute lymphocyte count (ALC) over time, duration of immune competence (ALC ≥1,000 cells/µL), disease-specific survival (DSS), and safety (treatment-emergent adverse events, serious adverse events, laboratory parameters, vital signs, and ECGs). The study also includes exploratory analyses of whole slide images and blood/tissue-based molecular profiling to explore correlations with clinical outcomes.

02

Conditions studied

  • NSCLC (Advanced Non-small Cell Lung Cancer)
  • Metastatic NSCLC

Keywords

  • non-small cell lung cancer
  • NSCLC
  • nogapendekin alfa inbakicept
  • NAI
  • ANKTIVA
  • IL-15 agonist
  • chemoimmunotherapy
  • pembrolizumab
  • platinum chemotherapy
  • pemetrexed
  • paclitaxel
  • nab-paclitaxel
  • progression-free survival
  • immunotherapy
  • molecular profiling
03

In context

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

ImmunityBio, Inc. is the lead sponsor of 83 studies on the registry; 14 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 17 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • confirmed stage IV NSCLC (squamous or nonsquamous).
  • No prior systemic chemotherapy for advanced/ NSCLC.
  • Tumor lacks an actionable genomic alteration with approved targeted therapy (EGFR, ALK etc.; AGA status from local or central testing; ctDNA acceptable if tissue unavailable).
  • PD L1 result available before randomization: TPS ≥1%, \<1%, or unknown.
  • performance status 0-1.
  • At least one per v1.1.
  • Able to attend visits and follow-up.
  • requirements for women of and nonsterile males, with 7 month post-last-dose window.

Exclusion criteria

Exclusion Criteria:

  • Body weight \<40 kg.
  • Serious uncontrolled concomitant disease.
  • Certain prior (exceptions: adequately treated or nonmetastatic, as per protocol).
  • Active disease requiring systemic treatment (exceptions: autoimmune thyroiditis, etc.).
  • Prior organ transplant requiring .
  • Prior pneumonitis/interstitial lung disease requiring active systemic treatment.
  • Prior systemic chemotherapy or immunotherapy within 3 years.
  • Requirement for other anticancer therapy while on study (palliative RT allowed).
  • Known , carcinomatous meningitis, and/or spinal cord compression (with specified exceptions for treated or asymptomatic brain mets).
  • infection or active/uncontrolled / not meeting the protocol's controlled criteria.
  • Active infection requiring IV therapy.
  • Inadequate organ function:
  • ANC \<1,500/mm³; \<100,000/mm³; \<9 g/dL.
  • Total >1.5× (with defined Gilbert's exception).
  • /ALT >1.5×ULN (or >5×ULN with liver mets).
  • ALP >2.5×ULN (or >5×ULN with bone mets).
  • \<40 mL/min (Cockcroft-Gault).
  • Significant cardiovascular disease (uncontrolled HTN, recent MI, stroke, CHF ≥ II, serious arrhythmia).
  • Known to study drugs.
  • Concomitant medications known to interact adversely with study drugs.
  • Participation in another drug/device study (except hormone-lowering therapy).
  • Pregnancy or breastfeeding.
  • Confinement by court order/authority.
  • Any condition or noncompliance that, in Investigator judgment, precludes participation.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Experimental: NAI + Pembrolizumab + Chemotherapy

    First-line stage IV NSCLC; induction (≤4 cycles) with pembrolizumab + platinum + nab-paclitaxel (squamous) or pemetrexed (nonsquamous) plus NAI, followed by maintenance pembrolizumab ± pemetrexed plus NAI.

    Drug: Drug: Nogapendekin alfa inbakicept (NAI) · Drug: Pembrolizumab · Drug: Cisplatin or Carboplatin · Drug: Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous)

  • Active comparator
    Active Comparator: Pembrolizumab + Chemotherapy

    First-line standard-of-care chemoimmunotherapy per pembrolizumab + platinum doublet regimens, histology-specific.

    Drug: Pembrolizumab · Drug: Cisplatin or Carboplatin · Drug: Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous) · Drug: Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous) · Drug: Pemetrexed (nonsquamous)

Interventions

  • 1.2 mg SC q3 weeks (15 μg/kg SC if ≥100 kg), up to 35 cycles.

  • 200 mg IV q3 weeks.

  • DrugCisplatin or Carboplatin

    Drug pages: Cisplatin · Carboplatin

    Cisplatin 75 mg/m² IV q3w OR carboplatin AUC 5-6 IV q3w (per label).

  • DrugNab-paclitaxel (squamous) OR Pemetrexed (nonsquamous)

    Squamous: nab-paclitaxel 100 mg/m² IV on Days 1, 8, 15 of cycles 1-4. Nonsquamous: pemetrexed 500 mg/m² IV Day 1 q3w, up to 35 cycles.

  • DrugNab-paclitaxel OR Paclitaxel OR Docetaxel (squamous)

    Nab-paclitaxel 100 mg/m² IV D1, 8, 15 or paclitaxel 175 mg/m² IV D1 or docetaxel 75 mg/m² IV D1 (per RHA label/local guidelines) for cycles 1-4 in squamous participants.

  • First-line standard-of-care chemoimmunotherapy per pembrolizumab + platinum doublet regimens, histology-specific.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) by BICR (RECIST v1.1)

    PFS is defined as the time from randomization to the first documentation of disease progression per RECIST v1.1 by blinded independent central review (BICR) or death from any cause, whichever occurs first.

    Time frame: Imaging every 9 weeks (±7 days) from first dose (after initial assessments at week 6 and week 12) until treatment discontinuation; final PFS analysis with follow-up through 156 weeks (3 years) from first dose.

Secondary outcomes

  1. Overall survival (OS)

    Time from randomization to death from any cause.

    Time frame: From first dose until death, with survival follow-up through 156 weeks (3 years) from first dose.

  2. Objective Response Rate (ORR) by BICR (RECIST v1.1)

    ORR is the proportion of participants with a confirmed complete response (CR) or partial response (PR) per RECIST v1.1 by BICR.

    Time frame: Imaging every 9 weeks (±7 days) from first dose (after initial assessments at week 6 and week 12) until treatment discontinuation; ORR assessed up to 156 weeks (3 years) from first dose.

  3. Change in Absolute Lymphocyte Count (ALC) Over Time

    Change from baseline in absolute lymphocyte count over time by treatment group.

    Time frame: At scheduled study visits from first dose through 156 weeks (3 years) from first dose or end of treatment, whichever occurs first.

  4. Duration of Immune Competence (ALC ≥1,000 cells/µL)

    Duration of immune competence, defined as the time during treatment that ALC remains ≥1,000 cells/µL.

    Time frame: From first dose until treatment discontinuation; duration of immune competence assessed up to 156 weeks (3 years) from first dose.

  5. Duration of Response (DOR) by BICR (RECIST v1.1)

    For participants with a confirmed CR or PR per RECIST v1.1 by BICR, DOR is defined as the time from the date of first documented response (CR or PR) to the date of disease progression per RECIST v1.1 by BICR or death from any cause, whichever occurs first.

    Time frame: Tumor imaging at week 6 and week 12 following Cycle 1 Day 1, then every 9 weeks (±7 days) from first dose until treatment discontinuation; DOR assessed up to 156 weeks (3 years) from first dose.

  6. Disease Control Rate (DCR) by BICR (RECIST v1.1)

    DCR is the proportion of participants with CR, PR, or stable disease (SD) lasting at least 2 months per RECIST v1.1 as assessed by BICR.

    Time frame: Tumor imaging at week 6 and week 12 following Cycle 1 Day 1, then every 9 weeks (±7 days) from first dose until treatment discontinuation; DCR assessed up to 156 weeks (3 years) from first dose.

  7. PFS, ORR, DOR, and DCR by BICR Using iRECIST

    PFS, ORR, DOR, and DCR assessed per immune RECIST (iRECIST) as determined by BICR, using the same definitions as for RECIST v1.1 but applying iRECIST rules.

    Time frame: Tumor imaging at week 6 and week 12 following Cycle 1 Day 1, then every 9 weeks (±7 days) from first dose until treatment discontinuation; each endpoint assessed up to 156 weeks (3 years) from first dose.

  8. PFS, ORR, DOR, and DCR by Investigator Assessment (RECIST v1.1 and iRECIST)

    PFS, ORR, DOR, and DCR per RECIST v1.1 and iRECIST as assessed by site Investigators, using the same definitions as for BICR.

    Time frame: Tumor imaging at week 6 and week 12 following Cycle 1 Day 1, then every 9 weeks (±7 days) from first dose until treatment discontinuation; each endpoint assessed up to 156 weeks (3 years) from first dose.

  9. Disease-specific survival (DSS)

    DSS is defined as the time from randomization to death due to NSCLC. Deaths from other causes are censored at the date of death.

    Time frame: From first dose until death due to NSCLC, with follow-up through 156 weeks (3 years) from first dose.

Other outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Number and proportion of participants with TEAEs and SAEs, graded using NCI CTCAE v6.0.

    Time frame: From signing of informed consent through 30 days after last dose of study drug; SAEs considered related to study treatment may be collected beyond this window, up to 156 weeks (3 years) from first dose for analysis.

  2. Changes in Clinical Laboratory Parameters

    Changes from baseline in hematology, chemistry, and urinalysis parameters, including ALC.

    Time frame: From first dose through 156 weeks (3 years) from first dose or 30 days after last dose, whichever occurs first.

  3. Changes in Vital Signs

    Changes from baseline in temperature, heart rate, blood pressure, and respiratory rate.

    Time frame: From first dose through 156 weeks (3 years) from first dose or 30 days after last dose, whichever occurs first.

  4. Changes in Electrocardiograms (ECGs)

    Incidence of new or worsening clinically relevant ECG abnormalities compared with baseline.

    Time frame: From first dose through 156 weeks (3 years) from first dose or 30 days after last dose, whichever occurs first.

  5. Correlation of Whole Slide Images With Clinical Outcomes

    Associations between histopathologic features derived from high-resolution whole slide images and clinical outcomes (PFS, OS, ORR, DOR, DCR).

    Time frame: From first dose through 156 weeks (3 years) from first dose.

  6. Correlation of Molecular Profiles With Clinical Outcomes

    Associations between tumor and blood-based molecular profiles (e.g., genomic and RNA analyses) and clinical outcomes (PFS, OS, ORR, DOR, DCR, ALC dynamics).

    Time frame: From first dose through 156 weeks (3 years) from first dose.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified participant-level data to be shared include: unique study ID; demographics and baseline characteristics (age, sex, ECOG, histology, PD-L1, AGA status); treatment assignment and exposure (dates offset, doses, modifications); efficacy outcomes and dates (tumor measurements, RECIST/iRECIST responses, PFS, OS, DOR, DCR); safety data (AEs/SAEs with MedDRA codes, CTCAE grade, relatedness); lab results, vitals/ECGs, concomitant meds; processed biomarker datasets and derived pathology/image features. Raw direct identifiers and physical specimens require separate agreements.

Supporting information: Clinical study report

Time frame: Start date: Data will be made available within 6 months after primary study results are published and any required regulatory review is complete. End date: Data access will be provided for 5 years from the start date.

Access criteria: Qualified researchers with approved proposals and ethics approval may access de-identified IPD (participant IDs, demographics, treatment/exposure, efficacy/safety outcomes, labs, processed biomarker and derived imaging data) and supporting documents (protocol, SAP, data dictionary) after signing a data use agreement. Data are provided via a secure controlled-access platform; requests are reviewed by the Sponsor.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for May 2029, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 13, 2026
StartEst.
May 29, 2026
Primary completionEst.
May 15, 2029
CompletionEst.
Dec 30, 2029
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07524257
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
May 29, 2026 (estimated)
Primary completion
May 15, 2029 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Jun 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nogapendekin alfa inbakicept

Start the discussion